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PreviewsIL-9-dependent mechanisms that include
growth and recruitment of mast cells and
basophils or lung and intestinal goblet
cell metaplasia in parasite immune re-
sponses. On the basis of these studies,
the new tools generated by Licona-Limo´n
et al. will allow researchers to INFER
further insight into the role of IL-9 in immu-
nity and inflammation.
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Blood CXCR5+ CD4+ T cells share phenotypic and functional similarities with T follicular helper cells. Studies
by He et al. (2013) and Locci et al. (2013) in this issue of Immunity provide insight into their ontogeny and
functionally distinct subsets.T follicularhelper (Tfh)cellsareCD4+Tcells
specialized for providing help to B cells
(Crotty, 2011). Tfh cells are identified by a
combination ofmarkers, including the che-
mokine receptor CXCR5, costimulatory
molecules ICOS and PD-1, and the
transcription repressor BCL6. The main
effector site of Tfh cells is germinal centers
(GCs) in secondary lymphoid organs, and
GC Tfh cells selectively provide help to
high-affinity B cells and promote their sur-
vival and differentiation into memory cells
and plasma cells. Accordingly, Tfh cells
are essential for the generation of protec-
tive antibody responses, whereas exag-
gerated or dysregulated Tfh responses
cause autoimmunity. A majority of these
conclusions were obtained from mouse
studies. An important question is whether
and how these observations can be trans-
lated in human immunology and applied to
understand human disease pathogenesis.
The challenge here is an extremely limited
accessibility to secondary lymphoid
organ samples from individuals with
diseases. An alternative approach is the
analysis of blood samples. Human bloodcontains memory CXCR5+ CD4+ T cells
that share phenotypic and functional prop-
erties with Tfh cells and therefore are often
called ‘‘blood Tfh cells’’ (hereinwealso use
this term for simplicity). In this issue of Im-
munity, studies by He et al. (2013) and
Locci et al. (2013) substantially extended
the knowledge on the ontogeny and sub-
sets of blood Tfh cells.
BCL6 is not expressed by blood Tfh
cells, even by ‘‘activated’’ ICOS+ PD-1+
subsets (Bentebibel et al., 2013; Chevalier
et al., 2011; He et al., 2013; Locci et al.,
2013; Morita et al., 2011). Thus, blood
Tfh cells are different from bona fide Tfh
cells in secondary lymphoid organs, and
direct evidence demonstrating a relation-
ship between blood Tfh cells and GC
Tfh cells has been lacking. Here, He
et al. showed that similar to GC Tfh cells,
the development of blood Tfh cells was
totally dependent on ICOS and BCL6.
Furthermore, they demonstrated that
an increase of ‘‘activated’’ Tfh subset in
blood (described later) correlates with
the magnitude of newly generated Tfh
cells in secondary lymphoid organs. Ofnote, unlike GC Tfh cells, the develop-
ment of blood Tfh cells did not require
SAP or GC formation (He et al., 2013),
suggesting that the major precursors of
blood Tfh cells are developing Tfh cells
rather than GC-Tfh cells. Nonetheless,
these observations suggest that ana-
lysis of blood Tfh subsets permits the
assessment of ongoing Tfh responses.
We previously showed that blood Tfh
cells are composed of functionally dis-
tinct subsets that share properties with
Th1, Th2, and Th17 cells, defined by the
differential expression of the chemokine
receptors CXCR3 and CCR6. Importantly,
whereas CXCR3 subsets (containing
CCR6 Th2- and CCR6+ Th17-like cells)
can help naive B cells to become immu-
noglobulin-producing plasmablasts, the
CXCR3+ Th1-like subset lacks this
capacity (Bentebibel et al., 2013; Morita
et al., 2011). The two new studies show
that that PD-1 expression can define
additional aspects of human blood Tfh
subsets (He et al., 2013; Locci et al.,
2013). Accordingly, human blood Tfh
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Figure 1. Human Blood Tfh Subsets
Studies by He et al. (2013) and Locci et al. (2013) provide insights regarding the ontogeny and functionally
distinct subsets of blood Tfh cells. Human blood Tfh cell cells can be divided into four subsets according to
the expression of CXCR3 and PD-1. CCR7 expression negatively correlates with PD-1 expression. The
PD-1+ subsets contain cells expressing ICOS, which represent ‘‘activated’’ blood Tfh cells. Among the
‘‘quiescent’’ blood Tfh subsets, the PD-1+CXCR3 subset is the most efficient at providing help to B cells.
The CXCR3+ subsets is able to provide help to B cells only when activated (ICOS+PD-1+ cells), but their
ability is limited to memory B cells.
Immunity
Previewsby the expression of CXCR3 and PD-1
(Figure 1). The PD-1+ subsets can be
further subdivided into two subgroups
according to the expression of ICOS.
The ICOS+PD-1+ subpopulations repre-
sent activated blood Tfh cells. These cells
are barely present in healthy individuals
(He et al., 2013; Locci et al., 2013) but
increase after influenza vaccination (Ben-
tebibel et al., 2013). He et al. concluded
that the PD-1+ subset expressing the
lowest amounts of CCR7 (thus the PD-1+
CCR7lo subset) represents activated
blood Tfh cells. This PD-1+CCR7lo subset
seems largely overlapping with the
ICOS+PD-1+ subsets because the PD-1+
CCR7lo subset contained ICOS+ cells
(He et al., 2013), and the kinetics of the in-
crease of PD-1+CCR7lo subset after influ-
enza vaccination (He et al., 2013) was
identical to that of the ICOS+PD-1+ subset
increase (Bentebibel et al., 2013).
The ICOSPD-1+ and the PD-1 blood
Tfh subsets did not express activation
markers and thus represent quiescent
blood Tfh subsets (He et al., 2013; Locci
et al., 2013). Locci et al. focused on the
analysis of the four quiescent ICOS
blood Tfh subsets and found that the
PD-1+CXCR3 subset displayed a gene-
expression profile the most similar to
that of tonsillar GC Tfh cells. Furthermore,
the PD-1+CXCR3 subset was the most630 Immunity 39, October 17, 2013 ª2013 Elefficient at inducing memory B cells
to differentiate into immunoglobulin G
(IgG)-producing plasmablasts. These re-
sults show that the PD-1+CXCR3 subset
is the most functional among the quies-
cent blood Tfh subsets.
These new findings will provide imme-
diate implications to the studies on human
blood Tfh cells. First, the integration of
PD-1, ICOS, and CCR7 together with
CXCR3 and CCR6 in the analysis of hu-
man blood Tfh cells will facilitate deter-
mining the phenotype correlating with
disease activity in human autoimmune
diseases and generation of protective
antibody responses in infections and vac-
cinations. Indeed, He et al. demonstrated
that the frequency of the PD-1+CCR7lo
subset positively correlated with disease
activity and the titers of several serum
autoantibodies in human autoimmune
diseases. Locci et al. found that the fre-
quency of PD-1+CXCR3 subset in blood
Tfh cells positively correlated with devel-
opment of broadly neutralizing antibodies
against HIV in a large cohort of HIV-in-
fected individuals.
Second, these studies have provided
the framework and the directions for the
future studies on the biology of human
blood Tfh cells. Remaining questions
include:What is the function of each blood
Tfh subset in vivo? How is the stability ofsevier Inc.each blood Tfh subset in vivo? Which
blood Tfh subsets represent ‘‘memory’’
Tfh cells that immediately differentiate
into GC Tfh cells and promote GC re-
sponses? What is the cause of the alter-
ation in the blood Tfh subsets in autoim-
mune diseases? Such studies will
provide substantial insights regarding the
pathogenesis of autoimmune diseases
and for the design of novel vaccines. For
example, in our recent study on influenza
vaccines, we showed that the vaccination
induces the emergence of the ICOS+
PD-1+ CXCR3+ Tfh subset in blood
(Figure 1). Despite the findings that the
CXCR3+ subsets are the least functional
(Locci et al., 2013;Morita et al., 2011), their
increase at day 7 after vaccination posi-
tively correlated with the generation of
protective antibody responses. We found
that the ICOS+PD-1+CXCR3+ Tfh cells
were able to induce memory B cells to
differentiate intoplasmacells thatproduce
influenza-specific antibodies ex vivo but
lacked the capacity to help naive B cells
(Bentebibel et al., 2013). These observa-
tions suggest that current influenza vac-
cine is largely dependent on the CXCR3+
Tfh subsets, which can help only memory
B cells, which likely explains its limited
efficacy. Together with the observation
by Locci et al. in HIV-infected individuals,
these studies suggest the importance of
the induction of CXCR3 Tfh responses
in humans for the generation of optimal
protective antibody responses.
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